Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$158.94
pos +0.64
+0.40%
Today's Range: 157.21 - 159.42 | AMGN Avg Daily Volume: 3,537,400
Last Update: 05/02/16 - 3:59 PM EDT
Volume: 2,433,172
YTD Performance: 0.00%
Open: $158.51
Previous Close: $158.30
52 Week Range: $130.09 - $181.81
Oustanding Shares: 752,091,038
Market Cap: 120,755,737,061
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 9 9 9 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.30 2.30 2.30 2.25
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
0.00 17.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $2.71 $2.78 $11.00 $11.95
Number of Analysts 10 9 12 9
High Estimate $2.81 $3.08 $11.70 $12.80
Low Estimate $2.62 $2.65 $10.63 $11.35
Prior Year $2.57 $2.72 $10.38 $11.00
Growth Rate (Year over Year) 5.60% 2.12% 5.97% 8.65%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Apr 28, 2016 | 10:00 AM EDT

This earnings season continues to disappoint, and technology names are leading the downward charge.

By

Bret Jensen

 | Apr 22, 2016 | 9:00 AM EDT

There are lots of winners in the first quarter.

By

Bret Jensen

 | Apr 21, 2016 | 10:00 AM EDT

It's important to focus on hitting singles in this overbought and earnings-starved environment.

By

Bret Jensen

 | Apr 19, 2016 | 10:00 AM EDT

This will still be fourth quarter in a row that profits have declined year over year.

By

Bret Jensen

 | Apr 1, 2016 | 11:00 AM EDT

In this choppy market, the sweet spot is large-caps with these three core attributes.

By

Jim Cramer

 | Mar 22, 2016 | 11:46 AM EDT

Jim Cramer said he is starting to see the beginnings of what could turn into a rally in the biotech sector.

By

Gary Morrow

 | Mar 21, 2016 | 2:32 PM EDT

It has multiple layers of resistance to work through to maintain a new bull leg.  

By

Bret Jensen

 | Mar 18, 2016 | 9:30 AM EDT

And yet, Endocyte has a deep pipeline.

By

Kate Stalter

 | Mar 17, 2016 | 10:00 AM EDT

It's better to broaden your exposure to avoid seeing your portfolio suffer.

By

Bret Jensen

 | Mar 15, 2016 | 11:00 AM EDT

I am starting to get more confident that the small caps are ready to bounce.

That could put an axe into the stock here near 30x forward earnings.  Comps were OK t...
CIRCOR International (CIR) ripping into the close on a basic upgrade.  The stock has ...
As we have previously said, Apple (AAPL) is inside our long-term bounce zone of $94.74-$85...

Average Cost= $20.22
Bidding on a scale lower.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.